FDA issues medtech appeals process guidance but will behaviour change at US agency?
This article was originally published in Clinica
The US Food and Drug Administration has issued final guidance explaining the various mechanisms that are available to device companies to appeal against decisions made by the agency's Center for Devices and Radiological Health.
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.
An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.